91 related articles for article (PubMed ID: 24659646)
1. Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer.
Cokmert S; Demir L; Can A; Akyol M; Vedat Bayoglu I; Dirican A; Kucukzeybek Y; Erten C; Oktay Tarhan M
J BUON; 2014; 19(1):75-82. PubMed ID: 24659646
[TBL] [Abstract][Full Text] [Related]
2. Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Bozkurt O; Berk V; Kaplan MA; Cetin B; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(6):2501-4. PubMed ID: 24761854
[TBL] [Abstract][Full Text] [Related]
3. Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response.
Arslan C; Aksoy S; Dizdar O; Kurt M; Güler N; Ozisik Y; Güllü I; Altundag K
Tumori; 2011; 97(6):711-6. PubMed ID: 22322836
[TBL] [Abstract][Full Text] [Related]
4. Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Scarabelli L; Giovanardi F; Gervasi E; Prati G; Pezzuolo D; Scaltriti L
Chemotherapy; 2013; 59(5):369-72. PubMed ID: 24821441
[TBL] [Abstract][Full Text] [Related]
5. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Dellapasqua S; Bagnardi V; Bertolini F; Sandri MT; Pastrello D; Cancello G; Montagna E; Balduzzi A; Mancuso P; Luini A; Goldhirsch A; Colleoni M
Breast; 2012 Jun; 21(3):309-13. PubMed ID: 22341133
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies.
Wenzel C; Mader RM; Steger GG; Pluschnig U; Kornek GV; Scheithauer W; Locker GJ
Anticancer Drugs; 2003 Feb; 14(2):119-23. PubMed ID: 12569298
[TBL] [Abstract][Full Text] [Related]
7. Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Inanc M; Duran AO; Karaca H; Berk V; Bozkurt O; Ozaslan E; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(1):253-6. PubMed ID: 24528035
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.
Buti S; Bordi P; Tiseo M; Bria E; Sperduti I; Di Maio M; Panni S; Novello S; Rapetti SG; Pilotto S; Genestreti G; Rossi A; Pezzuolo D; Camisa R; Tortora G; Ardizzoni A
Lung Cancer; 2015 Jun; 88(3):319-24. PubMed ID: 25870156
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
11. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
[TBL] [Abstract][Full Text] [Related]
12. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP
Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676
[TBL] [Abstract][Full Text] [Related]
15. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Bendell JC; Nemunaitis J; Vukelja SJ; Hagenstad C; Campos LT; Hermann RC; Sportelli P; Gardner L; Richards DA
J Clin Oncol; 2011 Nov; 29(33):4394-400. PubMed ID: 21969495
[TBL] [Abstract][Full Text] [Related]
16. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Petrioli R; Bargagli G; Lazzi S; Pascucci A; Francini E; Bellan C; Conca R; Martellucci I; Fiaschi AI; Lorenzi B; Francini G;
Anticancer Drugs; 2010 Mar; 21(3):313-9. PubMed ID: 20016369
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.
Vrdoljak E; Omrcen T; Boban M; Hrepic D
J BUON; 2008; 13(4):513-8. PubMed ID: 19145672
[TBL] [Abstract][Full Text] [Related]
18. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
19. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
20. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Vallböhmer D; Yang DY; Kuramochi H; Shimizu D; Danenberg KD; Lindebjerg J; Nielsen JN; Jakobsen A; Danenberg PV
Int J Oncol; 2007 Aug; 31(2):413-8. PubMed ID: 17611699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
